Adalimumab levels detected in cord blood and infants exposed in utero, researchers report
ScienceDaily (May 7, 2011) Adalimumab (ADA), a drug often prescribed for women with Crohn’s disease, actively crosses the placenta during the final trimester of pregnancy and remains in a newborn’s bloodstream for at least three months, researchers at the University of California San Francisco have found.
The new study has implications for pregnant women and their obstetricians and pediatricians because ADA is known to decrease the immune system’s capability to fight infection. Infants exposed in utero should be monitored closely for infection in the first six months of life and should not receive any live-virus vaccines during that time, cautioned lead researcher Uma Mahadevan, MD, who presented the latest findings at Digestive Disease Week® 2011, being held in Chicago.
“Since there is some placental transfer of adalimumab before birth, you have to be vigilant in the first six months of life for the baby,” stated Dr. Mahadevan, an associate professor of medicine. “However, our findings do not suggest that a pregnant woman should discontinue the drug. Stopping it actually can be more harmful to both baby and mom because of the risk of miscarriage, preterm birth and low birth weight if the Crohn’s disease flares.”
The study followed five pregnant women with Crohn’s disease who were taking ADA. On the day of delivery, ADA levels were measured in the mother, newborn and cord blood. In all cases, the cord blood showed higher levels than the maternal levels — indicating transfer from the mom — and significant ADA levels were found in three of the newborn samples. Levels continued to be checked in the infants until ADA could no longer be identified.
“At a minimum, it can be detected to three months from birth,” Dr. Mahadevan noted.
Dr. Mahadevan stated future studies should explore the effects of medications during children’s initial years as well as potential risks later in life because of their exposure in utero.
The above story is reprinted (with editorial adaptations by ScienceDaily staff) from materials provided by Digestive Disease Week, via EurekAlert!, a service of AAAS.
Note: If no author is given, the source is cited instead.
Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.
source : www.sciencedaily.com
Related News:
- New look at prolonged radiation exposure: At low dose-rate, radiation poses tiny risk to DNA, study suggests
- Toronto study links breakfast with school success
- Losing weight when obese can prevent or cure diabetes, whatever the initial BMI, study suggests
- Study links genes to common forms of glaucoma
- For Paul’s Believers, a Study in American Optimism
- Anxiety increases cancer severity in mice, study shows
- Study points to potential treatment for stroke
- Memory loss with aging not necessarily permanent, animal study suggests
- Prolonged fructose intake not linked to rise in blood pressure, study suggests
- Inherited risk factors for childhood leukemia are more common in Hispanic patients, study finds
Details :
Submited at Monday, May 9th, 2011 at 7:00 am on Health by admin
Comment RSS 2.0 - leave a comment - trackback